A Novel Recombinant Immuno-tBid With a Furin Site Effectively Suppresses the Growth of HER2-positive Osteosarcoma Cells in Vitro

Oncology Reports - Greece
doi 10.3892/or.2010.1074
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Spandidos Publications

Related search

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Knockdown of TRAF4 Expression Suppresses Osteosarcoma Cell Growth in Vitro and in Vivo

International Journal of Molecular Medicine
MedicineGenetics
2014English

MicroRNA‑497 Suppresses Osteosarcoma Tumor Growth In�vitro and In�vivo

Oncology Letters
Cancer ResearchOncology
2016English

A Novel Asymmetrical Anti-Her2/Cd3 Bispecific Antibody Exhibits Potent Cytotoxicity for HER2-positive Tumor Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer

The Open Breast Cancer Journal
2009English

A Novel Solid-Phase Site-Specific PEGylation Enhances the in Vitro and in Vivo Biostabilty of Recombinant Human Keratinocyte Growth Factor 1

PLoS ONE
Multidisciplinary
2012English

A Novel Taspine Derivative Suppresses Human Liver Tumor Growth and Invasion in Vitro and in Vivo

Oncology Letters
Cancer ResearchOncology
2013English

Silencing of E2F3 Suppresses Tumor Growth of Her2+ Breast Cancer Cells by Restricting Mitosis

Oncotarget
Oncology
2015English

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Cancer Research
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy